Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-26

Clinical Trial Update: Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating subcutaneous belimumab in pediatric patients with systemic lupus erythematosus. The study results were posted on 2024-03-26.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belimumab (belimumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-26